KROS

Keros Therapeutics, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $11.36
52-Week Range: $9.69 – $22.55
Market Cap: $228.41M
P/E (TTM): —
EPS (TTM): -3.22
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.87
PEG Ratio: —
Return on Equity: -17.16%
Return on Assets: -11.78%
Gross Margin: 0.00%
Operating Margin: -655.84%
Profit Margin: 0.00%
Current Ratio: 21.96
Debt/Equity: 0.06
Total Debt: $15.72M
Free Cash Flow: $-27.17M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-13.47M

KROS Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$151.00K	$3.55M	$244.06M
Research & Development	$87.27M	$135.26M	$173.63M	$129.64M
Selling, General & Admin	$27.52M	$34.83M	$40.75M	$46.85M
Operating Expenses	$107.71M	$167.69M	$213.15M	$176.49M
Operating Income	-$107.71M	-$167.54M	-$209.59M	$67.57M
EBITDA	-$104.00M	-$152.18M	-$208.37M	$69.08M
Pretax Income	-$104.68M	-$152.99M	-$187.05M	$91.90M
Income Tax	$0.00	$0.00	$300.00K	$4.88M
Net Income	-$104.68M	-$152.99M	-$187.35M	$87.01M
Diluted EPS	-4.15	-5.20	-5.00	2.30
Diluted Shares	23.44M	29.45M	37.44M	37.86M

KROS Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$279.05M	$331.15M	$559.93M	$287.42M
Receivables	$841.00K	$1.09M	$4.46M	$6.37M
Current Assets	$285.77M	$347.29M	$588.89M	$315.43M
Total Assets	$306.78M	$370.02M	$615.89M	$338.02M
Current Liabilities	$16.55M	$24.37M	$27.45M	$20.41M
Total Debt	$13.27M	$14.44M	$18.86M	$16.88M
Total Liabilities	$29.36M	$37.81M	$44.33M	$34.89M
Retained Earnings	-$228.43M	-$381.43M	-$568.78M	-$481.76M
Shareholders' Equity	$277.42M	$332.21M	$571.55M	$303.13M
Working Capital	$269.22M	$322.92M	$561.44M	$295.02M

KROS Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$70.06M	-$124.51M	-$160.87M	$107.50M
Capital Expenditure	-$1.24M	-$2.46M	-$1.93M	-$1.55M
Free Cash Flow	-$71.30M	-$126.97M	-$162.80M	$105.95M
Depreciation & Amortisation	$674.00K	$815.00K	$1.23M	$1.51M
Stock-Based Compensation	$18.68M	$28.76M	$34.87M	$28.70M
Investing Cash Flow	-$1.24M	-$2.46M	-$1.93M	-$1.55M
Financing Cash Flow	$120.31M	$178.96M	$391.82M	-$378.47M
Share Repurchases	—	—	$0.00	-$375.00M
Net Change in Cash	$49.01M	$51.98M	$229.02M	-$272.52M

KROS Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$211.25M	$18.17M	$14.26M	$385.00K	$367.00K	$0.00
Research & Development	$48.71M	$43.50M	$19.52M	$17.91M	$16.10M	$22.33M
Selling, General & Admin	$10.50M	$14.48M	$10.13M	$11.74M	$10.15M	$8.61M
Operating Expenses	$59.21M	$57.98M	$29.65M	$29.66M	$26.24M	$30.94M
Operating Income	$152.04M	-$39.82M	-$15.38M	-$29.27M	-$25.88M	-$30.94M
EBITDA	$152.38M	-$39.45M	-$14.99M	-$28.87M	-$25.47M	-$30.54M
Pretax Income	$158.49M	-$32.92M	-$8.70M	-$24.98M	-$23.71M	-$28.71M
Income Tax	$10.04M	-$2.22M	-$1.42M	-$1.51M	$0.00	$0.00
Net Income	$148.45M	-$30.70M	-$7.28M	-$23.46M	-$23.71M	-$28.71M
Diluted EPS	3.62	-0.76	-0.18	-0.86	-1.21	-1.45
Diluted Shares	41.02M	40.61M	40.62M	27.20M	19.63M	19.80M

KROS Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$720.54M	$690.22M	$693.47M	$287.42M	$281.50M	$257.61M
Receivables	$19.37M	$17.74M	$5.57M	$6.37M	$2.96M	$2.76M
Current Assets	$759.51M	$732.81M	$719.31M	$315.43M	$290.68M	$266.88M
Total Assets	$784.56M	$757.16M	$742.78M	$338.02M	$312.29M	$287.60M
Current Liabilities	$39.38M	$34.71M	$24.09M	$20.41M	$12.85M	$12.15M
Total Debt	$18.41M	$17.95M	$17.43M	$16.88M	$16.31M	$15.72M
Total Liabilities	$55.69M	$50.43M	$39.20M	$34.89M	$26.66M	$25.28M
Retained Earnings	-$420.33M	-$451.02M	-$458.30M	-$481.76M	-$505.47M	-$534.18M
Shareholders' Equity	$728.87M	$706.73M	$703.58M	$303.13M	$285.63M	$262.32M
Working Capital	$720.13M	$698.10M	$695.22M	$295.02M	$277.82M	$254.73M

KROS Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	$161.17M	-$29.62M	$3.25M	-$27.29M	-$3.53M	-$20.42M
Capital Expenditure	-$565.00K	-$720.00K	-$132.00K	-$134.00K	-$73.00K	-$155.00K
Free Cash Flow	$160.61M	-$30.34M	$3.12M	-$27.43M	-$3.60M	-$20.58M
Depreciation & Amortisation	$344.00K	$370.00K	$395.00K	$400.00K	$403.00K	$402.00K
Stock-Based Compensation	$8.86M	$8.54M	$3.99M	$7.30M	$6.20M	$5.38M
Investing Cash Flow	-$565.00K	-$720.00K	-$132.00K	-$134.00K	-$73.00K	-$155.00K
Financing Cash Flow	$4.00K	$17.00K	$140.00K	-$378.63M	-$2.32M	-$3.31M
Net Change in Cash	$160.61M	-$30.33M	$3.26M	-$406.06M	-$5.92M	-$23.89M

Market Snapshot

About

Keros Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for diseases caused by dysfunctional signaling of the transforming growth factor-beta (TGF-beta) family of proteins. The company's lead programs target hematologic and musculoskeletal disorders including myelodysplastic syndromes, pulmonary arterial hypertension, and fibrodysplasia ossificans progressiva. Keros leverages its expertise in TGF-beta biology to develop therapeutics addressing significant unmet medical needs.